Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis (SHOP-G01)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Peking University
Information provided by (Responsible Party):
Jiafu Ji, Peking University Identifier:
First received: November 1, 2011
Last updated: December 6, 2012
Last verified: December 2012

The recurrence and metastasis of peritoneum is always the lethal consequence for gastric cancer patients, and there is no effective therapy until now. It has been reported by Dr.Fujimoto that intraperitoneal chemotherapy plus hyperthermic therapy, which called hyperthermic intraperitoneal chemotherapy (HIPEC), can eliminate and suppress the free cancer cells and tiny metastasis in abdomen. Refer to the experience of systematic chemotherapy, HIPEC with combination regimen would have a brighter prospect. In this study, the investigators would use Oxaliplatin and paclitaxel sequent as HIPEC regimen. The safety and overall survival would be observed and evaluated.

Condition Intervention Phase
Gastric Cancer
Metastases to Perineum
Drug: Oxaliplatin
Drug: Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study of Sequential Hyperthermic Intraperitoneal Chemotherapy of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis or Positive Free Cancer Cells in Abdomen

Resource links provided by NLM:

Further study details as provided by Peking University:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: every 3 month postoperation up to 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety [ Time Frame: every 3 month postoperation up to 24 months ] [ Designated as safety issue: Yes ]
    Number of Participants with Adverse Events(III or IV grades according to NCI-CTC)

Estimated Enrollment: 20
Study Start Date: September 2011
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HIPEC Drug: Oxaliplatin
Oxaliplatin 345mg/m2,43℃,30mins
Drug: Paclitaxel
Paclitaxel 260mg/m2,43℃,30mins


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proved gastric adenocarcinoma.
  • Peritoneum metastasis is observed or suspected by laparoscopy or radiologic examination,or free cancer cells are detected in peritoneal lavage liquid.
  • Potentially resectable gastric cancer.
  • ALT, AST < 80U/L; Total Bilirubin < 30μmol/L; WBC > 4x10^9/L; PLT > 100x10^9/L; Cr < 1.5 fold normal value.
  • ECOG 0-2 points.
  • Expected survival time longer than 3 months.
  • Informed consent.

Exclusion Criteria:

  • Recurrent gastric cancer.
  • Pregnant or lactating women.
  • Allergic to oxaliplatin or paclitaxel.
  • Abnormal liver/kidney function.
  • Serious heart/metabolic disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01471132

Contact: Xiaojiang Wu 8601088196598

China, Beijing
Peking University Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Sponsors and Collaborators
Peking University
Study Chair: Jiafu Ji Beijing Cancer Hospital
  More Information

No publications provided

Responsible Party: Jiafu Ji, Director, Peking University Identifier: NCT01471132     History of Changes
Other Study ID Numbers: HIPEC-GCOT
Study First Received: November 1, 2011
Last Updated: December 6, 2012
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Neoplasm Metastasis
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Stomach Diseases
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on November 25, 2014